| 体内研究: |
I-BET567 (compound 27) (3, 10, and 30 mg/kg; p.o.; once daily for 20 days) leads to a significant reduction in tumor growth compared with vehicle controls at both 10 and 30 mg/kg. Assessment of Pharmacokinetics (PK) profile of I-BET567 following intravenous infusion and oral administration in male wistar han rat and beagle doga. |
| 参考文献: |
1. Humphreys PG, et al. Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate [published online ahead of print, 2022 Jan 7]. |
| 保存条件: |
避光,-80℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.779 ml |
13.896 ml |
27.792 ml |
| 5 mM |
0.556 ml |
2.779 ml |
5.558 ml |
| 10 mM |
0.278 ml |
1.39 ml |
2.779 ml |
| 50 mM |
0.056 ml |
0.278 ml |
0.556 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |